ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,805 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselSynendos Therapeutics AG
Synendos Therapeutics AG Logo
Verified· 3 sources

Synendos Therapeutics AG

Summary

About the company

The core activity of Synendos Therapeutics AG is the development of pharmaceuticals, particularly the research and development of active ingredients and medicines in various therapeutic areas, including clinical trials and approval. The company focuses on the development of medicines for various diseases, including neurological disorders, and offers services in the fields of medicinal chemistry, pharmacology, clinical research and development.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered4
Development of SERI therapeutics
Development of Selective Endocannabinoid Reuptake Inhibitors (SERIs) for the treatment of neuropsychiatric disorders; first-in-class small molecules with a new mechanism of action.
Clinical development of SYT-510
Clinical development of the lead candidate SYT-510, including completed preclinical work and Phase 1 studies, as well as a planned Phase 2a study in generalized anxiety disorder.
Development of additional ECS modulators
Development of additional selective endocannabinoid reuptake inhibitors and alternative ECS modulators in an early development phase for neuropsychiatric disorders.
Research on endocannabinoid system therapies
Research on the endocannabinoid system as a new therapeutic approach to restore brain function in neuropsychiatric and other CNS disorders.
Press

Media

August 14, 2025Media
Four startups welcome new leaders to accelerate growth
startupticker.ch
November 12, 2020Media
Synendos Therapeutics secures CHF 20 million
startupticker.ch

Knowledge

No knowledge articles yet

Once Synendos Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Synendos Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Synendos Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Synendos Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Barfüsserplatz 3
4051 Basel

At a glance

Legal form
Corporation
UID
CHE-145.781.587
Founded
2019 · 7 years
Last commercial register change
July 31, 2025
Employees
21 to 50

Similar companies

SA
SpiroChem AG
Basel
SA
Scailyte AG
Basel
TT
TargImmune Therapeutics AG
Basel
3B
3T Biosciences Europe GmbH
Basel